MYELODYSPLASTIC SYNDROME. Vivienne Fairley Clinical Nurse Specialist Sheffield
|
|
- Randolph Eric Powers
- 6 years ago
- Views:
Transcription
1 MYELODYSPLASTIC SYNDROME Vivienne Fairley Clinical Nurse Specialist Sheffield
2 MDS INCIDENCE 1/100,000/YEAR 3,250/YEAR MEDIAN AGE 70
3 MDS HYPO OR HYPERCELLULAR BONE MARROW BLOOD CYTOPENIAS (EARLY STAGES DUE TO APOPTOSIS) INEFFECTIVE BLOOD PRODUCTION ALL 3 LINES CAN BE AFFECTED PRODUCE CELLS THAT HAVE LOST THEIR ABILITY TO DIFFERENTIATE PREMALIGNANT PRIMARY OR SECONDARY(60-70% NO CAUSATIVE FACTOR)
4 SIGNS AND SYMPTOMS BONE MARROW FAILURE- anaemia, bleeding, frequent infections SPLENOMEGALY CMML ~50% ASYMPTOMATIC AND HAVE AN INCIDENTAL FINDING
5 DIAGNOSIS FULL BLOOD COUNT AND FILM?BONE MARROW ASPIRATE AND TREPHINE( 5-19% BLAST CELLS AND DYSPLASTIC FEATURES IN >10% CELLS)?CYTOGENETICS RULE OUT OTHER CAUSES(MEGALOBLASTIC ANAEMIA, HIV, ALCOHOLISM, RECENT CHEMOTHERAPY, SEVERE CONCOMMITANT ILLNESS) PNH CLONAL STUDIES FULL HISTORY FAMILY HISTORY MDS/AML FERRITIN, FOLATE, B12
6 MDS VARYING CLINICAL CONDITION INDOLENT TO AGGRESSIVE RA(REFRACTORY ANAEMIA) PROLONGED CLINICAL COURSE LOW RISK PROGRESSION TO AML RAEB(refractory anaemia with excess blasts) SHORT CLINICAL COURSE MORE LIKELY TO TRANFORM TO AML
7 WHO CLASSIFICATION OF MDS DISEASE BLOOD BONE MARROW REFRACTORY ANAEMIA(RA) RA WITH RINGED SIDEROBLASTS(RARS) ANAEMIA NO OR RARE BLASTS ANAEMIA NO BLASTS ERYTHROID DYSPLASIA ONLY, <5% BLASTS ERYTHROID DYSPLASIA ONLY, <5% BLASTS, >15% RINGED SIDEROBLASTS REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA(RCMD) RCMD-RS REFRACTORY ANAEMIA WITH EXCESS BLASTS 1(RAEB-1) RAEB-2 MDS UNCLASSIFIED(MDS-U) MDS WITH DELETED 5Q(MDS del5(q)) CYTOPENIAS NO OR RARE BLASTS CYTOPENIAS NO OR RARE BLASTS CYTOPENIAS <5% BLASTS CYTOPENIAS 5-19% BLASTS CYTOPENIAS NO OR RARE BLASTS ANAEMIA <5% BLASTS DYSPLASIA IN >10% CELLS IN 2 OR MORE MYELOID LINES, <5% BLASTS DYSPLASIA IN >10% CELLS IN 2 OR MORE MYELOID LINES, <5% BLASTS, >15% RINGED SIDEROBLASTS UNI OR MULTILINEAGE DYSPLASIA 5-19% BLASTS UNI OR MULTILINEAGE DYSPLASIA 10-19% BLASTS UNILINEAGE DYSPLASIA IN GRANULOCYTES OR MEGAKARYOCYTES <5% BLASTS NORMAL INCREASED MEGAKARYOCYTES, <5% BLASTS, ISOLATED del5(q)
8 MDS IPSS SCORE BASED ON CYTOPENIAS, CYTOGENETICS AND BLAST PERCENTAGE AGE NEW WHO SCORE TAKING INTO ACCOUNT TRANSFUSION REQUIREMENTS
9 IPSS-R cytogenetics Very good good int poor Very poor blasts <5% 5-10% 11-30% Hb >/- 10 <10 platelets >/- 100 <100 ANC >/-0.8 <0.8
10 PROGNOSTIC RISK 1. Very low Good >2-3.5 GROUPS/SCORES 3. Intermediate > High > Very high >6 For consideration of age (age in years-70)x 0.04, add result to sum of other variables
11 IPSS-R: PROGNOSTIC SUBGROUP CLINICAL OUTCOMES( median in years) Very low Good Intermediate Poor Very high OS (overall survival) AML 25% NR
12 CATEGORIES AND SURVIVAL SUBTYPE % CASES SURVIVAL MONTHS RA 8 69 RCMD RARS RAEB RAEB q RCMDRS 15 32
13 PROGNOSTIC FACTORS GOOD YOUNGER, NORMAL OR MODERATELY LOW NEUTOPHILS AND PLATELETS, LOW BLASTS IN BONE MARROW, NO BLASTS IN PERIPHERAL BLOOD, NO AUER RODS OR RINGED SIDEROBLASTS, NORMAL OR MIXED KARYOTYPE WITHOUT COMPLEX CYTOGENETICS, NO LEUKAEMIC GROWTH PATTERN IN CULTURE POOR ADVANCED AGE, SEVERE NEUTROPENIA AND THROMBOCYTOPENIA, BLASTS IN PERIPHERAL BLOOD, ABOVE 20% BLASTS IN BONE MARROW, AUER RODS, ABNORMAL OR COMPLEX KARYOTYPE, LEUKAEMIC GROWTH PATTERN IN CULTURE
14 LOW RISK DISEASE APPROX 2/3 HAVE LOW RISK DISEASE LOW INT-1 IPSS SCORE BUT CAN HAVE A POOR PROGNOSIS EXISTING TOOLS DO NOT DIFFERENTIATE FOR THIS DECREASED SURVIVAL IF PLATELETS <50, AGE >60, UNFAVOURABLE CYTOGENETICS, Hb<10, BLASTS IN BONE MARROW >4-10% 30% PROGRESS TO AML
15 TRIALS TRANSPLANT GROWTH FACTORS SUPPORTIVE TREATMENT REVLIMID(5q-)70% CYTOGENETIC RESPONSE LOW DOSE ARA-C HYDROXYCARBAMIDE 5 AZACITADINE CHEMOTHERAPY IRON CHELATION
16 TREATMENT - TRIALS INTENSIVE TREATMENT POTENTIALLY LEADING TO TRANSPLANT MUST BE HIGH RISK MDS WITH >10% BLASTS IN BONE MARROW UNDER 60 AML 17 OVER 60 NO CURRENT TRIAL AVAILABLE
17 TREATMENT CHEMOTHERAPY STANDARD TREATMENT OFF TRIAL DA 3+10 LOW DOSE S/C CYTARABINE HYDROXYCARBAMIDE
18 TREATMENT 5-AZACITADINE EXERT AN ANTICANCER EFFECT BY CAUSING DNA DEMETHYLATION OR HYPOMETHYLATION IN ABNORMAL MARROW CELLS RESTORE NORMAL FUNCTION TO THE TUMOUR SUPPRESSOR GENES RESPONSIBLE FOR REGULATING CELL DIFFERENTIATION AND GROWTH RETARDS THE PROGRESSION OF MDS TO AML COMPARED TO BEST SUPPORTIVE CARE 5-AZA HAD A 60% LONGER TIME TO PROGREESION TO AML AND AN IMPROVEMENT IN QUALITY OF LIFE, BUT NO SURVIVAL BENEFIT PHASE III TRIAL 5-AZA INCREASED OS AND 2 YEAR SURVIVAL DOUBLED COMPARED TO CONVENTIONAL THERAPY TREATMENT 75MG/M2(CAN BE INCREASED IF TOLERATED) S/C FOR 7 DAYS EVERY 4 WEEKS MAIN SIDE EFFECTS INJECTION SITE INFLAMMATION, INITIAL LOWREING OF BLOOD COUNTS
19 TREATMENT LENALIDOMIDE THOUGHT TO INTERFERE WITH THE IMMUNE SYSTEM AND ACTS ON ANGIOGENESIS IN-VIVO HAS DIRECT ANTI-TUMOUR EFFECTS, INHIBITS THE MICRO-ENVIRONMENT SUPPORT FOR TUMOUR CELLS AND HAS AN IMMUNOMODULATORY ROLE IN-VITRO INDUCES TUMOUR CELL APOPTOSIS DIRECTLY, AND INDIRECTLY INHIBITS BONE MARROW STROMAL CELL SUPPORT, ANTI-ANGIOGENIC AND ANTIOSTEROCLASTIC EFFECTS ON TRIAL 63% OF PATIENTS ACHIEVED RBC INDEPENDENCE ACCOMPANIED BY A MEDIAN INCREASE OF 5.8G/Dl Hb MAJOR CYTOGENETIC RESPONSE 44% MINOR 24% 10MG PO FOR DAYS AS LONG AS EFFECTIVE INCREASED RISK OF PROGRESSING TO AML RESPONSE AROUND~2 YEARS
20 TREATMENT ATG ANTI-LYMPHOCYTE GLOBULIN USED IN CONJUNCTION WITH CYCLOSPORIN HYPOPLASTIC MDS? AUTO-IMMUNE COMPONENT 5 DAYS ATG WITH ~6 MONTHS CYCLOSPORIN
21 TREATMENT GROWTH FACTORS G-CSF AND EPO EFFECTIVENES OF EPO~ 30% IN MDS PHASE II STUDY SHOWED A RESPONSE OF 60% IN LOW RISK IPSS WITH SERUM EPO LEVELS<500U/L? COMBINATION INCREASES EFFICACY A REANALYSIS OF DATA DEMONSTRATED A BETTER RESPONSE IN RARS(70%) THAN RCMD-RS(9%)? DUE TO ABILITY OF G-CSF TO INHIBIT CYTOCHROME C RELEASE AND HENCE MITOCHONDRIA MEDIATED APOPTOSIS IN RARS ERYTHROBLASTS WAITING FOR TRIAL START DATE
22 TREATMENT SUPPORTIVE G-CSF BLOOD/PLATELET TRANSFUSIONS PREVENTATIVE ANTIMICROBIALS NURSE LED CLINICS HOME VISITS DECISIONS RE TREATMENT
23 TREATMENT IRON CHELATION RECOMMENDATIONS FOR IRON CHELATION BASED ON LIMITED DATA EVIDENCE SUGGESTS THAT IRON OVERLOAD CAN LEAD TO ORGAN FAILURE AND MORBIDITY IN THE BONE MARROW IT MAY ADD TO EARLY CELLULAR APOPTOSIS CONTROLLED BY MICROENVIRONMENT TRIAL OF 170 PATIENTS WITH MDS 76 RECEIVED CHELATION OS 115 MONTHS VS 51 IN NON CHELATED SHOULD BE CONSIDERED WHEN A PATIENT HAS RECEIVED 5G OF IRON( APPROX 25 UNITS OF RED CELLS) ONLY IN PATIENTS REQUIRING LONG TERM TRANSFUSION THERAPY WITH LIFE EXPECTANCY OF 2-4+ YEARS TWO MAIN METHODS SUB-CUTANEOUS DESFERRIOXAMINE(DESFERRAL) AND ORAL DEFERASIROX(EX- JADE)
24 TREATMENT IRON CHELATION DESFERRAL S/C OVER 12 HOURS UP TO 5 DAYS EACH WEEK INFUSORS OR SYRINGE DRIVERS EXCRETED RENALLY( CAUTION IN RENAL INSUFFICIENCY) INCREASED RISK OF YERSINIA INFECTIONS NEED YEARLY EYE/HEARING TESTS NEED TO REDUCE DOSE WHEN FERRITIN LEVELS FALL BELOW 1000ug/L( normal range ug/L) VITAMIN C ENHANCES SECRETION SIDE EFFECTS PAIN, SWELLING, INFLAMMATION AT INJECTION SITE, VERY RARE ANAPHYLAXIS, DIZZINESS
25 TREATMENT IRON CHELATION EX-JADE ORAL PREPARATION ONCE DAILY DOSING ½ LIFE 8-16 HOURS FAECALLY ELIMINATED TAKEN ON AN EMPTY STOMACH 30MINS BEFORE FOOD NEED REGULAR U+E BLOOD TEST SIDE EFFECTS ALLERGIC REACTIONS, NAUSEA, WORSENING RENAL/LIVER FUNCTION, RASH, FLU-LIKE SYMPTOMS, DIARRHOEA
26 ? TO CHELATE COMPLICATIONS OF IRON OVERLOAD DEVELOP AFTER MANY YEARS OF TARGET ORGAN EXPOSURE MORE THAN 85% PATIENTS ARE DIAGNOSED OVER THE AGE OF 60 WITH 3 YEAR SURVIVAL BEING 35% MDS IN A LOW RISK CATEGORY BUT REQUIRING TRANSFUSIONS OFTEN ASSOCIATED WITH INFERIOR OS AND LEUKAEMIA FREE SURVIVAL SERUM FERRITIN USED AS A MARKER OF IRON OVERLOAD CORRELATES WITH TRANSFUSION LOAD DIFFICULT TO DECIPHER ITS INDEPENDENT PROGNOSTIC VALUE MYOCARDIAL OR HEPATIC IRON DEPOSITION SELDOM CITED AS A CAUSE OF DEATH IN MDS
27 SUPPORTIVE CARE INFORMATION, EDUCATION MDM SURVIVORSHIP HOLISTIC ASSESSMENT FERTILITY LEUKAEMIA CARE, WILLOW FOUNDATION KEYWORKER NURSE LED CLINIC HOME VISITS DN/ MACMILLAN DLA/AA/MACMILLAN GRANTS DIETETIC/OT/PT/SW SUPPORT GROUPS(MDS UK PATIENT SUPPORT GROUP, LOCAL GROUP)
28 READING LIST HEALTHLIBRARY.EPRET.COM EMEDICINE NORTH TRENT HAEMATO-ONCOLOGY NETWORK GUIDELINES VERSION 1 FEBRUARY 2007 GARCIA-MANERO ET AL 2008; A PROGNOSTIC SCORE FOR PATIENTS WITH LOWER RISK MDS LEUKAEMIA 22(3) SCHMID ET AL 2009; EX-JADE IS EFFECTIVE AND WELL TOLERATED IN CHELATION NAÏVE AND PREVIOUSLY CHELATED PATIENTS IN TRANSFUSION DEPENDANT MDS BLOOD 111(22) LIST ET AL 2009; 2 YEAR ANALYSIS OF EFFICACY OF DESFERRIOX TREATMENT IN MDS BLOOD 114(22) FOX ET AL 2009; MATCHED PAIR ANALYSIS OF 186 MDS PATIENTS RECEIVING CHELATION THERAPY OR TRANSFUSION THERAPY ONLY BLOOD 114(22) TEFFERI ET AL 2009; IRON CHELATION THERAPY IN MDS- CUI BONO LEUKAEMIA MALCOVATI ET AL 2005; PROGNOSTIC FACTORS AND LIFE EXPECTANCY IN MDS CLASSIFIED ACCORDING TO WHO CRITERIA J CLIN ONCOL FENAUX ET AL 2007;AZACITADINE TREATMENT PROLONGS OVERALL SURVIVAL IN HIGHER RISK MDS PATIENTS COMPARED WITH CONVENTIONAL CARE REGIMENS ASH ANNUAL MEETING ABSTRACTS LIST ET AL 2006; LENALIDOMIDE IN THE MDS SYNDROME WITH CHROMOSOME 5q DELETION N ENG J MED GREENBERG ET AL 1989; INTERNATIONAL SCORING SYSTEM FOR EVALUATING PROGNOSIS IN MDS BLOOD (6) LIST ET AL 2005; EFFICACY OF LENALIDOMIDE IN MDS N ENG J MED (6) SILVERMAN ET AL 2006; FURTHER ANALYSIS OF TRIALS WITH AZACITADINE IN PATIENTS WITH MDS J CLIN ONCOL 24(24)
29 READING LIST VARDIMAN 2006: HAEMATOPATHOLOGICAL CONCEPTS AND CONTROVERSIES IN THE DIAGNOSIS OF MDS HAEMATOLOGY AMERICAN SOCIETY OF HAEMATOLOGY AUL ET AL : EMERGING TREATMENT OPTIONS FOR ADULT MDS: A CLINICAL PERSPECTIVE MDS FOUNDATION INC FENAUX ET AL 2006; TREATMENT OF THE 5q- SYNDROME AMERICAN SOCIETY OF HAEMATOLOGY DE WITTE ET AL 2007: AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR MDS BLOOD REVIEWS BENNETT 2008; CONSENSUS STATEMENT ON IRON OVERLOAD IN MDS AMERICAN JOURNAL OF HAEMATOLOGY 1-4
Table 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationmyelodysplastic syndrome MDS MDS MDS
myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory
More informationMyelodysplastic syndromes
Haematology 601 Myelodysplastic syndromes The myelodysplastic syndromes are a group of disorders predominantly affecting elderly people, leading to ineffective haematopoiesis, and they have the potential
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationNetwork Guidance Document. Oncological treatment of Haematology. Myelodysplastic Syndromes (MDS) Final. Status: November 2012.
Network Guidance Document Oncological treatment of Haematology Myelodysplastic Syndromes (MDS) Status: Final Expiry Date: November 2012 Version Number: 1 Publication Date: November 2010 Page 1 of 14T:\DOG
More informationMDS - Diagnosis and Treatments. Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital
MDS - Diagnosis and Treatments Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital Overview What is myelodysplasia? Symptoms Diagnosis and prognosis Myelodysplasia therapy
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 2 Dr Helen Barker MDT Lead
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationA prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.
Protocol Synopsis Study Title A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes. Short Title European MDS
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationGuidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS)
Guidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS) Author: Dr A Pillai, Consultant Haematologist On behalf of the Haematology CNG Re- Written: February 2011, Version 2 Revised:
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 1 Dr Helen Barker MDT Lead
More informationMyelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona
Myelodysplastic syndrome Jeanne Palmer, MD Mayo Clinic, Arizona What is Myelodysplastic syndrome? A disease where the bone marrow doesn t work appropriately What does that mean?? Red blood cells Carry
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationAbout Myelodysplastic Syndromes
About Myelodysplastic Syndromes Overview and Types If you have been diagnosed with a myelodysplastic syndrome or are worried about it, you likely have a lot of questions. Learning some basics is a good
More informationACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016
Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationImpact of Comorbidity on Quality of Life and Clinical Outcomes in MDS
Current Therapeutic and Biologic Advances in MDS A Symposium of The MDS Foundation ASH 2014 Impact of Comorbidity on Quality of Life and Clinical Outcomes in MDS Peter Valent Medical University of Vienna
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationMyelodysplastic syndromes in adults aged less than 50 years: Incidence and clinicopathological data
JBUON 2014; 19(4): 999-1005 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Myelodysplastic syndromes in adults aged less than 50 years: Incidence
More informationOverview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
Int J Hematol (2008) 88:24 29 DOI 10.1007/s12185-008-0118-z PROGRESS IN HEMATOLOGY Transfusional iron overload and iron chelation therapy Overview of guidelines on iron chelation therapy in patients with
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationScottish Medicines Consortium
Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationMyelodysplastic scoring system with flow cytometry. G Detry B Husson
Myelodysplastic scoring system with flow cytometry G Detry B Husson Myelodysplastic syndroms Clonal haematopoietic stem cell disease characterized by dysplasia in one or more of the myeloid cell lines
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationMyelodysplastic Syndromes
Myelodysplastic Syndromes Jennifer Rogers MS, FNP Cancer Center of the Carolinas Greenville, SC The Myelodysplastic Syndromes Overview Clonal disorder characterized by hypercellular marrows, peripheral
More informationRory McCulloch. Specialty Trainee Haematology Royal Devon & Exeter Hospital
Rory McCulloch Specialty Trainee Haematology Royal Devon & Exeter Hospital Anaemia 1 Haematological disorders Anaemia 2 Non-haematological disorders Substrates: Iron, folate, vitamin B12 Red cell mass
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationMyelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management
Myelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management Christa Roe, RN, BS, OCN Malignant Hematology Department H Lee Moffitt Cancer Center & Research Tampa, Florida Agenda MDS Disease
More informationNOVEL APPROACHES IN THE CLASSIFICATION AND RISK ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES-CLINICAL IMPLICATION
ORIGINAL ARTICLES NOVEL APPROACHES IN THE CLASSIFICATION AND RISK ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES-CLINICAL IMPLICATION Ilina Micheva 1, Rosen Rachev 1, Hinco Varbanov 1, Vladimir
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationUnderstanding & Treating Myelodysplastic Syndrome (MDS)
Understanding & Treating Myelodysplastic Syndrome (MDS) Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Let s Look at Our
More informationRAEB-2 2 Transforming to Acute Erythroleukemia Case # 165
RAEB-2 2 Transforming to Acute Erythroleukemia Case # 165 Sebastian J. Sasu, M.D. UCLA Medical Center, Hematopathology Los Angeles, CA and Saint John s s Health Center Santa Monica, CA Clinical History
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Azacitidine i INDICATION ICD10 Regimen Code *Reimbursement Status Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationCorrespondence should be addressed to Anas Khanfar;
Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion
More informationMyelodysplastic syndromes
Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationDarbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes
NIHR Innovation Observatory Evidence Briefing: August 2017 Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes NIHRIO (HSRIC) ID: 13763
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationMyelodysplastic syndromes and the new WHO 2016 classification
Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital
More informationINTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS
INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS Saturday, September 29, 2018 Cyrus C. Hsia, HBSc, MD, FRCPC Associate Professor of Medicine, Schulich School of Medicine and Dentistry, Western
More informationMyelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support
Myelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support LLS Mission & Goals Our mission. Cure leukemia, lymphoma, Hodgkin s disease and myeloma, and improve the quality of life of patients and
More informationMyelodysplastic Syndrome
Myelodysplastic Syndrome A Family-Oriented Approach on Diagnosis and Treatment Options Cecilia Arana Yi, MD Assistant Professor MDS Patient & Family/Caregiver Forum March 3, 2018 Quote of the Day There
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationMyelodysplastic Syndromes: Update in Diagnosis and Therapy. Peter Valent
Myelodysplastic Syndromes: Update in Diagnosis and Therapy Peter Valent MDS: Typical Features - Dysplasia in one or more Cell Lineages in the BM - Peripheral Cytopenia (unilineage, bi-, or pan-cp) - Quality
More informationManagement of low and high risk MDS
Management of low and high risk MDS D.Selleslag AZ Sint-Jan Brugge, Belgium Brussels, 4th October 2014 Low / int 1 risk MDS Improve QOL Improve cytopenia Int 2 / high risk MDS Delay progression To AML
More informationAnemia (2): 4 MS/18/02/2019
Anemia (2): 4 MS/18/02/2019 Case 2 65 yr old male had gradual onset of odd behavior with psychotic symptoms, irritability and parasthesia in hands and feet He was noticed to have imbalanced gait. Examination
More informationMDS overview 전남대학교김여경
MDS overview 전남대학교김여경 2008 WHO Classification of MDS Name Abbreviation Key Feature Pts, % Refractory cytopenia, with unlineage, dysplasia Refractory anemia with ring sideroblasts RA Anemia and erythroid
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationTreatment of Myelodysplastic Syndromes in Elderly Patients
Adv Ther (2011) 28(Suppl.2):1-9. DOI 10.1007/s12325-011-0001-9 REVIEW Treatment of Myelodysplastic Syndromes in Elderly Patients Jesus Feliu Sanchez Received: December 14, 2010 / Published online: March
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationShould lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France
Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationAzacitidine for Treatment of Myelodysplastic Syndrome (MDS)
Azacitidine for Treatment of Myelodysplastic Syndrome (MDS) Cumbria, Northumberland, Tyne & Wear Area Team DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Site Notes 1 to 5 Azacitidine 75 mg/m 2 subcutaneous
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph C l i n i c a l A d v a n c e s i n H e m a t o l o g y & O n c o l o g y J u l y 2 0 0 9 Treatment Selection for Myelodysplastic Syndrome Patients in the Community Setting
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationA Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Lewis R. Silverman, MD 1, Katherine Hearn, RN 2, Rosalie
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationAplastic Anemia & MDS International Foundation Talk. Definition. Introduction 4/20/2012. April 2012 H. Phillip Koeffler, M.D.
Aplastic Anemia & MDS International Foundation Talk April 2012 H. Phillip Koeffler, M.D. Definition Myelo Greek prefix; marrow Dysplasia abnormal morphology Can affect: RBCs WBCs Plts Introduction 1949:
More informationMyelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Received: 2 October 2017 Accepted: 2 October 2017 DOI: 10.1002/ajh.24930 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and
More informationMyelodysplastic Syndromes
NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Myelodysplastic Syndromes Version 1.2011 Continue www.nccn.org Version 1.2011, 10/27/10 National Comprehensive Cancer Network, Inc.
More informationLauren Cosolo, RN, BScN, MN
Bone Marrow Failure Diseases: Including MDS, AA, PNH Lauren Cosolo, RN, BScN, MN Outline Review bone marrow failure and disease Discuss Myelodysplastic syndrome, pathophysiology, clinical presentation,
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationMyelodysplastic syndromes post ASH Dominik Selleslag AZ Sint-Jan Brugge
Myelodysplastic syndromes post ASH 2016 Dominik Selleslag AZ Sint-Jan Brugge Why did they put MDS at the end of the meeting? Possible explanations Least fascinating disease without progress? Poor speaker?
More informationGuidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Nordic MDS Group
Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Nordic MDS Group Issue 6 5th update, 1 st of December 2011 1 INTRODUCTION... 4 WRITING COMMITTEE...
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationCause of Death in Patients With Lower-Risk Myelodysplastic Syndrome
Original Article Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome Farshid Dayyani, MD, PhD 1 ; Anthony P. Conley, MD 1 ; Sara S. Strom, PhD 2 ; William Stevenson, MBBS, PhD 3 ; Jorge
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationMyelodysplastic Syndromes
Please complete our online survey at NCCN GUIDELINES FOR PATIENTS NCCN.org/patients/survey 2018 Myelodysplastic Syndromes Presented with support from: Available online at NCCN.org/patients Ü Myelodysplastic
More informationClinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
Anwar et al. Molecular Cytogenetics (2017) 10:17 DOI 10.1186/s13039-017-0318-4 RESEARCH Open Access Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
More informationMyelodysplastic Syndromes (MDS) FAQs for Nurses
Myelodysplastic Syndromes (MDS) FAQs for Nurses Find answers to the most commonly asked questions about MDS from nurses and patients. This content meets the Oncology Nursing Society guidelines for quality
More informationAPPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE
APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics Department of Hematopathology The University
More informationJuvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic
More informationMDS FDA-approved Drugs
MDS: Current Thinking on the Disease, Diagnosis, and Treatment Mikkael A. Sekeres, MD, MS Associate Professor of Medicine Director, Leukemia Program Dept of Hematologic Oncology and Blood Disorders Taussig
More informationPiper Jaffray Healthcare Conference
Piper Jaffray Healthcare Conference John Scarlett, M.D. President and CEO, Geron Corporation November 2018 Forward-Looking Statements Except for statements of historical fact, the statements contained
More informationBorderline cytopenias. Dr Taku Sugai Consultant Haematologist
Borderline cytopenias Dr Taku Sugai Consultant Haematologist Borderline cytopenias Neutropenia Thrombocytopenia Anaemia with normal haematinics Two recent cases of cytopenias Neutropenia ANC of more than
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationEnglish Edition (USA)
English Edition (USA) You or someone you know has been diagnosed with MDS. Hearing the words Myelodysplastic Syndrome or MDS can be frightening. The diagnosis of MDS is often unexpected and filled with
More informationMyelodysplastic Syndromes: WHO 2008
Myelodysplastic Syndromes: WHO 2008 Attilio Orazi, M.D., FRCPath. (Engl.) Weill Medical College of Cornell University New York, NY Congresso Nazionale SIE - Società Italiana di Ematologia - MIC Milano
More informationBetter Prognosis for Patients With Del(7q) Than for Patients With Monosomy 7 in Myelodysplastic Syndrome
Better Prognosis for Patients With Del(7q) Than for Patients With Monosomy 7 in Myelodysplastic Syndrome Iris Cordoba, MD 1 ; José R. González-Porras, MD 1 ; Benet Nomdedeu, MD 2 ; Elisa Luño, MD 3 ; Raquel
More informationNew and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)
Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber
More informationPan-London Haemato-Oncology Clinical Guidelines. Acute Leukaemias and Myeloid Neoplasms Part 5: Myelodysplastic Syndromes
Pan-London Haemato-Oncology Clinical Guidelines Acute Leukaemias and Myeloid Neoplasms Part 5: Myelodysplastic Syndromes September 2018 CONTENTS Contents 1 Introduction... 3 2 Referral Pathways... 4 3
More information7/24/2017. MDS: Understanding Your Diagnosis and Current and Emerging Treatments. Hematopoiesis = Blood Cell Production
: Understanding Your Diagnosis and Current and Emerging Treatments Erica Warlick, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation University of MN Objectives Overview
More informationAllogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms Policy Number: 8.01.21 Last Review: 1/2019 Origination: 12/2001 Next Review: 1/2020 Policy Blue
More informationLeukaemia Section Review
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Review Classification of myelodysplasic syndromes Georges Flandrin Laboratoire d'hématologie,
More information